Education
About Us
Working with TipRanks
Follow Us
TMED - ETF AI Analysis
Top Page
T. Rowe Price Health Care ETF (TMED)
Rating:65Neutral
Price Target:―
Positive Factors
Leading Health Care Companies
The ETF’s largest positions include well-known, established health care leaders that have generally shown solid performance, helping support the fund’s recent gains.
Focused Health Care Exposure
By concentrating almost entirely on the health care sector, the fund gives investors targeted access to a key defensive area of the market that can hold up relatively well in different economic conditions.
Recent Performance Momentum
The ETF has shown steady gains over the past three months and year to date, indicating improving momentum in its underlying holdings.
Negative Factors
High Stock Concentration
A large portion of the fund is invested in a small number of companies, so performance is heavily influenced by how those few stocks behave.
Single-Sector Risk
With nearly all assets in health care, the ETF is vulnerable to sector-specific setbacks such as regulatory changes, drug pricing pressures, or industry-wide slowdowns.
Limited Geographic Diversification
The fund is almost entirely invested in U.S. companies, offering little protection if the U.S. health care market faces challenges.
TMED vs. SPDR S&P 500 ETF (SPY)
AUM20.91M
RegionGlobal
Expense Ratio0.44%
Beta0.60
IssuerT. Rowe Price
Inception DateJun 11, 2025
Dividend YieldN/A
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume3,752
30 Day Avg. Volume4,458
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
40.04Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering103
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
TMED Summary
TMED is the T. Rowe Price Health Care ETF, an actively managed fund that focuses on health care companies, mainly in the U.S. It does not track a fixed index, but instead lets T. Rowe Price’s team pick stocks they believe can outperform. The fund holds well-known names like Eli Lilly and UnitedHealth, along with other drug makers, medical device firms, and health care service providers. Investors might consider TMED for growth potential and targeted exposure to the health care sector. A key risk is that it is heavily concentrated in health care, so it can rise or fall with that sector.
How much will it cost me?The T. Rowe Price Health Care ETF (TMED) has an expense ratio of 0.44%, which means you’ll pay $4.40 per year for every $1,000 invested. This is higher than the average for ETFs because it is actively managed, with experts carefully selecting and adjusting the fund’s holdings to try to outperform traditional health care sector indices.
What would affect this ETF?The TMED ETF could benefit from advancements in biotechnology and medical innovation, as well as increasing global demand for health care services driven by aging populations and emerging markets. However, it may face challenges from regulatory changes, patent expirations, or economic downturns that could impact health care spending and the profitability of its top holdings. Additionally, fluctuations in interest rates could affect the broader market and investor sentiment toward health care stocks.
TMED Top 10 Holdings
TMED is a pure health care play, and its story right now is one of a few heavyweights losing steam while smaller names quietly pull their weight. Eli Lilly, the fund’s largest holding, has been sliding this year, and UnitedHealth and Thermo Fisher are also lagging, acting like a brake on returns. Abbott and Danaher look more mixed, with solid businesses but choppy trading. On the brighter side, Gilead and niche players like Cytokinetics and Elanco are rising, helping offset some of the drag in this globally diversified health care basket.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 14.99% | $3.13M | $962.75B | 15.55% | 72 Outperform | |
| UnitedHealth | 6.90% | $1.44M | $261.06B | -37.82% | 72 Outperform | |
| Abbott Laboratories | 4.29% | $896.85K | $197.00B | -16.83% | 73 Outperform | |
| Thermo Fisher | 4.19% | $875.19K | $192.95B | -4.06% | 72 Outperform | |
| Gilead Sciences | 3.76% | $786.58K | $189.50B | 37.70% | 78 Outperform | |
| Danaher | 3.20% | $668.61K | $147.32B | -0.35% | 75 Outperform | |
| Cytokinetics | 2.40% | $500.59K | $8.19B | 35.18% | 57 Neutral | |
| Elanco Animal Health | 2.38% | $497.47K | $12.31B | 126.68% | 69 Neutral | |
| Medtronic | 2.18% | $454.82K | $126.27B | 7.69% | 80 Outperform | |
| Becton Dickinson | 2.13% | $444.50K | $52.02B | -18.48% | 67 Neutral |
TMED Technical Analysis
Positive
―
Price Trends
29.86
Negative
29.20
Positive
Market Momentum
-0.10
Negative
48.47
Neutral
76.81
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For TMED, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 29.70, equal to the 50-day MA of 29.86, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 48.47 is Neutral, neither overbought nor oversold. The STOCH value of 76.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TMED.
TMED Peer Comparison
Comparison Results
Performance Comparison
TMED
T. Rowe Price Health Care ETF
29.65
4.84
19.51%
FMED
Fidelity Disruptive Medicine ETF
―
―
―
MEDI
Harbor Health Care ETF
―
―
―
MEDX
Horizon Kinetics Medical ETF
―
―
―
BMED
Future Health ETF
―
―
―
JDOC
JPMorgan Healthcare Leaders ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents